Publication Date:
2012-11-16
Description:
Cancer metabolism has received a substantial amount of interest over the past decade. The advances in analytical tools have, along with the rapid progress of cancer genomics, generated an increasingly complex understanding of metabolic reprogramming in cancer. As numerous connections between oncogenic signalling pathways and metabolic activities emerge, the importance of metabolic reprogramming in cancer is being increasingly recognized. The identification of metabolic weaknesses of cancer cells has been used to create strategies for treating cancer, but there are still challenges to be faced in bringing the drugs that target cancer metabolism to the clinic.〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Schulze, Almut -- Harris, Adrian L -- 11359/Cancer Research UK/United Kingdom -- NF-SI-0611-10163/Department of Health/United Kingdom -- Cancer Research UK/United Kingdom -- England -- Nature. 2012 Nov 15;491(7424):364-73. doi: 10.1038/nature11706.〈br /〉〈span class="detail_caption"〉Author address: 〈/span〉Gene Expression Analysis Laboratory, Cancer Research UK, London Research Institute, 44 Lincoln's Inn Fields, London WC2A 3LY, UK. almut.schulze@cancer.org.uk〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/23151579" target="_blank"〉PubMed〈/a〉
Keywords:
Animals
;
Cell Proliferation
;
Humans
;
Lipids/biosynthesis
;
Mitochondria/metabolism
;
Neoplasms/diagnosis/*metabolism/physiopathology/therapy
;
Oncogenes/physiology
;
Signal Transduction
;
Tumor Suppressor Proteins/metabolism
Print ISSN:
0028-0836
Electronic ISSN:
1476-4687
Topics:
Biology
,
Chemistry and Pharmacology
,
Medicine
,
Natural Sciences in General
,
Physics
